NASDAQ: ARCT
Arcturus Therapeutics Holdings Inc.
Healthcare · Biotechnology
After hours: $7.40(+0.49%) · as of 7:10 PM ET
Market Cap
$209.19M
52w High
$24.17
52w Low
$5.85
P/E
-2.66
Volume
375.18K
Outstanding Shares
28.42M
Price vs Fundamentals
Why The Stock Is Moving
What changed
The stock fell 40.07% over the last year. Revenue declined 66.45% over the trailing twelve months. Operating margin moved from -60.72% to -196.72%. Free cash flow grew 34.47% over the trailing twelve months.
What the market seems to be pricing
The market is reacting to weaker business momentum more than just compressing the valuation multiple. Even if the shares already screen cheap on P/S, investors are still discounting lower future earnings power.
What would invalidate this read
Operating margin stands at -196.72%. Revenue declined 66.45% — this read reverses if that trend stabilizes. If margins and cash flow stabilize while the stock stays depressed, the gap shifts from fundamental damage toward pure multiple compression.
Company profile
Arcturus Therapeutics Holdings Inc. is a biotechnology company focused on RNA-based medicines, developing a pipeline of vaccines for infectious diseases alongside treatments for rare liver and respiratory conditions across the United States.
Valuation
Stock splits
Every 7 shares became 1
Profitability & growth
Analyst consensus
12
Buy
5
Hold
4
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Aug 10, 2026
Q3 FY26 · EPS est -$1.00 · Revenue est $3.2M
View